Just-Evotec awarded DOD contract worth up to $74M
Seattle-based biologics company Just-Evotec has announced a new contract with the Department of Defense worth a potential $74 million.
The collaboration aims to create monoclonal antibodies that can be replicated by researchers and used to target toxins or foreign substances in the body. Just-Evotec will be responsible for analyzing existing monoclonal antibodies and uncovering new ones.
Just-Evotec hopes to create a prototype of an antibody drug that targets orthopoxviruses, including monkeypox and cowpox.
Headquartered in South Lake Union, the company began as Just Biotherapeutics in 2014 and was acquired by German biologics company Evotec in 2019.
(Photo: Courtesy Just-Evotec)